Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) reported on Wednesday that its founded entity biopharmaceutical company Karuna Therapeutics Inc (Nasdaq: KRTX) has won acceptance of its New Drug Application (NDA) for KarXT by the US Food and Drug Administration (FDA).
KarXT, co-invented by PureTech, is aimed at treating schizophrenia in adults.
The Prescription Drug User Fee Act (PDUFA) action date is set for 26 September 2024.
If approved, KarXT, based on the EMERGENT clinical trial data, could mark a groundbreaking pharmacological approach to schizophrenia treatment, representing PureTech's third successful venture from inception to FDA approval.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment